Abstract
Photodynamic therapy (PDT) consists of topical or systemic delivery of photosensitizing drugs followed by irradiation with light. Topical PDT is currently carried out with 5-aminolaevulinic acid (ALA) or methylaminolaevulinate (MAL) both metabolized in the cells to protoporphyrinIX (PpIX), a photosensitizing molecule absorbing visible light. As the rate of ALA-induced PpIX synthesis and accumulation is higher in malignant cells than in normal ones, PDT is able to exert a selective action on neoplastic tissues. PpIX transfers its energy to molecular oxygen generating reactive oxygen species. The subsequent oxidation of lipids, amino acids and proteins together with transcription and release of inflammatory mediators induces cell necrosis, apoptosis and immunemodulation. ALA 20% or MAL 16% (solution or cream) are applied over the skin lesion and then irradiated with blue or red light, depending on the thickness of the tumour. No anaesthesia is needed. Usually two-three treatments are sufficient for actinic keratosis, basal cell carcinoma, Bowens disease, the main dermatologic indications for PDT. Topical PDT is well suited for lesions that would otherwise require extensive surgical procedures and for patients with contraindications to surgery or with multiple lesions. We review action mechanism, procedures and indications of PDT for non-melanoma skin cancers.
Keywords: Photodynamic therapy, skin cancer, treatment, photosensitizing substances, 5-aminolevulinic acid, methylaminolaevulinate
Current Cancer Therapy Reviews
Title: Photodynamic Therapy For Non-Melanoma Skin Cancers
Volume: 5 Issue: 4
Author(s): Giuseppe Monfrecola, Gabriella Fabbrocini and Piergiacomo Calzavara Pinton
Affiliation:
Keywords: Photodynamic therapy, skin cancer, treatment, photosensitizing substances, 5-aminolevulinic acid, methylaminolaevulinate
Abstract: Photodynamic therapy (PDT) consists of topical or systemic delivery of photosensitizing drugs followed by irradiation with light. Topical PDT is currently carried out with 5-aminolaevulinic acid (ALA) or methylaminolaevulinate (MAL) both metabolized in the cells to protoporphyrinIX (PpIX), a photosensitizing molecule absorbing visible light. As the rate of ALA-induced PpIX synthesis and accumulation is higher in malignant cells than in normal ones, PDT is able to exert a selective action on neoplastic tissues. PpIX transfers its energy to molecular oxygen generating reactive oxygen species. The subsequent oxidation of lipids, amino acids and proteins together with transcription and release of inflammatory mediators induces cell necrosis, apoptosis and immunemodulation. ALA 20% or MAL 16% (solution or cream) are applied over the skin lesion and then irradiated with blue or red light, depending on the thickness of the tumour. No anaesthesia is needed. Usually two-three treatments are sufficient for actinic keratosis, basal cell carcinoma, Bowens disease, the main dermatologic indications for PDT. Topical PDT is well suited for lesions that would otherwise require extensive surgical procedures and for patients with contraindications to surgery or with multiple lesions. We review action mechanism, procedures and indications of PDT for non-melanoma skin cancers.
Export Options
About this article
Cite this article as:
Monfrecola Giuseppe, Fabbrocini Gabriella and Pinton Calzavara Piergiacomo, Photodynamic Therapy For Non-Melanoma Skin Cancers, Current Cancer Therapy Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339409789712663
DOI https://dx.doi.org/10.2174/157339409789712663 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report
Current Drug Safety The S100A8 and S100A9 Proteins are Attractive Targets to Modulate Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry On the Interaction of β-Amyloid Peptides and α7-Nicotinic Acetylcholine Receptors in Alzheimer’s Disease
Current Alzheimer Research Chemoprevention of Skin Carcinomas in High-Risk Transplant Recipients
Current Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry The Injured Cochlea as a Target for Inflammatory Processes, Initiation of Cell Death Pathways and Application of Related Otoprotective Strategies
Recent Patents on CNS Drug Discovery (Discontinued) Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology Cutaneous Melanoma: Fishing with Chips
Current Molecular Medicine Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Medium-term Culture of Normal Human Oral Mucosa: A Novel Three-dimensional Model to Study the Effectiveness of Drugs Administration
Current Pharmaceutical Design Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors
Current Drug Targets Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry